Sovremennye podkhody k terapii bol'nykh tsirrozom pecheni


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main directions in the management of cirrhotic patients include influence on the causative factor, the reduction of pathogenic reactions supporting the activity of the process, prevention of cirrhosis progression, treatment of symptoms and complications of the disease, and liver transplantation. The main components of the basic therapy (clinical nutrition, restoration of digestion processes and the structure of intestinal microflora), and drugs used for the treatment of portal hypertension and the prevention of portal crises are discussed. The role of hepatoprotectors and practical approach to their selection in liver cirrhosis are considered. Schemes of therapy of liver cirrhosis and main complications of portal hypertension - hepatic encephalopathy, ascites, ascites-peritonitis, and hepatorenal syndrome - are presented.

Full Text

Restricted Access

References

  1. Kuntz E, Kuntz H-D. Hepatology, Textbook and Atlas. Verlag: Springer Medizin Verlag Heidelberg. 2008:923.
  2. Sugimura Т, Tsuji Y, Sakamoto M, Kotoh K. Long term prognosis and prognostic factors of liver cirrhosis in the 1980s. J Gastroenterol Hepatol 1994;9:154-61.
  3. Шерлок Ш, Дули Д. Заболевания печени и желчных путей. Практическое руководство: Пер. с англ. / Под редакцией З.Г. Апросиной, И.А. Мухина. М., 1999. 964 с.
  4. Яковенко Э.П., Агафонова Н. А, Яковенко А.В. и др. Синдром избыточного бактериального роста в кишечнике - клиническое значение и вопросы терапии // Consilium medicum 2006. Экстравыпуск. С. 3-8.
  5. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Bacterial flora in digestive disease. Focus on rifaximin Eds. Scarpignato С, Lanas A. Basel: Karger, 2006:15-39.
  6. Williams R, Rizzello F, Venturi A, et al. Antibiotic of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multicentre study. Eur J Gastroenterol Hepatol 2000;12:203-08.
  7. Zakim D, Boyer TD. Hepatology. A textbook of liver disease. 4th ed. Saunders Science (USA), 2003:1765.
  8. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis В virus. Gastroenterology 1995;109:908-16.
  9. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
  10. Weinstein WM, Hawkey CJ, Bosch J. Clinical Gastroenterology and Hepatology. Elsevie, 2005:1128.
  11. Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol - induced hepatitis fibrosis in baboons. J Clin Gastroenterol 2003;37:336-39.
  12. Ma X, Zhao J, Lieber CS. Polyenylpho-sphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 1996;24:604-13.
  13. Яковенко Э. П., Яковенко А. В., Иванов А.Н. и др. Лекарственно-индуцированные поражения печени. Диагностика и лечение // Лечащий врач 2011. № 2. С. 16-20.
  14. Bissel DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: Zakim D, Boyer TD. (eds) Hepatology. A textbook of liver disease. 4th ed. Saunders Science (USA), 2003:395-416.
  15. Mathurin P, Carithers RL, Phillips M, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255-60.
  16. Григорьев П.Я., Яковенко А.В. Клиническая гастроэнтерология М., 2004. 748 с.
  17. Kamata Y, Nara H, Sato H, et al. Effect of steroid pulse therapy on mixed connective tisse disease with pulmonary arterial hypertension. Ann Rheum DIs 2005;64:1236-37.
  18. Wong F. Management of ascites in cirrhosis. J Gastroenterol Hepatol 2012;27:11-20.
  19. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. Hepatology 1999;30:639-45.
  20. Tandon P, Tsuyuki RT, Mitchell L, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009;29:169-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies